Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults

OBJECTIVE: Atopic dermatitis is a chronic, relapsing inflammatory skin disease characterized by intense pruritus, excoriations and limited therapies. Dupilumab, a monoclonal antibody against interleukin-4 receptor alpha, is a promising new treatment option for atopic dermatitis. We sought to systema...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xinghua, Zheng, Yi, Zhang, Xin, He, Yanling, Li, Chengxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752457/
https://www.ncbi.nlm.nih.gov/pubmed/29312544
http://dx.doi.org/10.18632/oncotarget.22499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752457/
https://www.ncbi.nlm.nih.gov/pubmed/29312544
http://dx.doi.org/10.18632/oncotarget.22499

Ejemplares similares